Document |
Document Title |
WO/2024/011136A1 |
Described herein are crystalline forms of 1-(5-((7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7
-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fl
uorocyclopropyl)urea adipate, and solvates thereof.
|
WO/2024/009280A1 |
The present disclosure provides compositions comprising proteins and/or constructs comprising a coding sequence encoding an integrated stress response (ISR) inhibitory protein and/or a characteristic portion thereof. Exemplary constructs...
|
WO/2024/010379A1 |
The present invention relates to a pharmaceutical composition that contains sustained-release microspheres composed of semaglutide or a pharmacologically acceptable salt thereof, a bioavailability enhancer, and a biodegradable polymer an...
|
WO/2024/008722A2 |
The present invention relates to compounds useful for modulating Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). The invention also relates to the compounds for use in treatment of conditions related to loss of function of TR...
|
WO/2024/008709A1 |
Using Harlequin (Hq) mice (a model developing an ataxic phenotype), the present inventors have confirmed that neuroglobin-based gene therapy represents a very promising tool for the treatment of neurological diseases. Hq mice were subjec...
|
WO/2024/011155A1 |
Described herein are oxazole TRPML1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TRPML1-mediated disorders or diseases.
|
WO/2024/010896A1 |
The present invention is directed to methods for treating macular degeneration, atherosclerosis, fatty liver, obesity, and cognitive ability, and more specifically to methods for treating macular degeneration, atherosclerosis, fatty live...
|
WO/2024/011214A1 |
The disclosure provides a compound of formula I: or a salt thereof, wherein R1, R2, R4, L1, L2, and A have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds 5 ar...
|
WO/2024/010963A1 |
The present disclosure provides phosphonate-containing heterocycle compounds with TYK2/JAK1 inhibitory activities, pharmaceutical compositions comprising the same, and applications thereof. The present disclosure provides compounds of Fo...
|
WO/2024/010045A1 |
The present invention relates to a pain suppressant for the trigeminal nerve, the pain suppressant containing tramadol or a salt thereof.
|
WO/2024/010772A1 |
Disclosed herein are small molecule compounds that are capable of inhibiting NLRP3 family proteins and NLRP3 inflammasome function in various disease settings. The disease is characterized by a disease progression pathology that comprise...
|
WO/2023/185156A9 |
A polypeptide compound and a preparation method therefor and an application thereof. The polypeptide compound has a structure as shown in formula I. The polypeptide compound can significantly improve the spatial learning and memory capab...
|
WO/2024/008166A1 |
Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represen...
|
WO/2024/009308A1 |
The present invention involves novel TRPV2 blockers, pharmaceutical compositions comprising the same and uses thereof for the treatment of inflammatory response in inflammation mediated disease processes.
|
WO/2024/008088A1 |
Disclosed are a class of compounds as TRK inhibitor drugs or RET inhibitor drugs and use thereof. Specifically, disclosed is use of a compound represented by formula (G), or an isotope-labeled compound thereof, or an optical isomer, a ge...
|
WO/2024/010067A1 |
The purpose of the present invention is to provide a nucleic acid molecule, a vector, recombinant cells, and a drug for treating a central nervous system disease which is likely to migrate into the central nervous system. The nucleic aci...
|
WO/2024/003711A1 |
The present invention relates to compositions comprising marine derived phospholipids for ameliorating at least one aging hallmark selected from the group consisting of genomic instability, telomere shortening, an epigenetic alteration, ...
|
WO/2024/005156A1 |
The present invention addresses the problem of providing a novel nucleic acid drug capable of simultaneously achieving both a high gene regulatory effect and a low toxicity. Provided is a toxicity reducing agent for a nucleic acid drug...
|
WO/2024/007031A1 |
Cannabinoids are a promising and potent class of agents in the management of pain, and preclinical studies in rodent models suggest that cannabinoids may be particularly potent in relieving neuropathic pain. Despite the potential benefit...
|
WO/2024/004500A1 |
Problem The purpose of this invention is to provide a new treatment method for epilepsy that solves the problems of current epilepsy treatment and has long-term effects. Solution The present invention is a method of treating a disease, c...
|
WO/2024/006906A1 |
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form o...
|
WO/2024/003787A1 |
The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase-5 (PDE-5) inhibitor and an anti-diabetic therapeutic including sodium-glucose cotransporter 2 (SGLT2) inhi...
|
WO/2024/006853A1 |
Disclosed herein is a method of treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depr...
|
WO/2024/005045A1 |
The present invention addresses the problem of providing a nucleic acid medicine which is capable, in a cell-specific manner, of capturing, and/or inhibiting the function of, a nucleic acid binding protein for which drug development is d...
|
WO/2024/005187A1 |
The composition according to the present disclosure includes edaravone and is used to change the expression level of a gene product in a target. The gene product is a gene product from one or more genes selected from KAZALD1, SBK1, SCN2A...
|
WO/2024/003389A1 |
The present invention relates to an anti-mGLUR2 biparatopic nanobody comprising : (i) one single domain antibody having a CDR1 having a sequence set forth as SEQ ID NO:1, a CDR2 having a sequence set forth as SEQ ID NO:2and a CDR3 having...
|
WO/2024/003377A1 |
The invention relates to a nutritional composition comprising a combination of (i) co-enzyme Q10 with (ii) vitamin D and (iii) vitamin B2, for use in the treatment of stroke, preferably ischemic stroke. The invention also relates to a co...
|
WO/2024/005526A1 |
The present invention relates to a novel compound as an NADPH oxidase 2 inhibitor and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits selective and excellent inhib...
|
WO/2024/005158A1 |
The problem addressed by the present invention is to identify a cis element that negatively regulates translation to protein present in DGCR8 mRNA or DGCR8 pre-mRNA, to provide an oligonucleotide capable of promoting expression of DGCR8 ...
|
WO/2024/003128A1 |
The present invention relates to a synthetic peptide comprising the following elements from the N-terminus to the C-terminus: a) a first cell-penetrating peptide or functional fragments or derivatives, or biologically active variants the...
|
WO/2024/006288A1 |
Described are novel aminosterol compounds and additionally aminosterol-cyclodextrin formulations suitable for injectable administration, and methods of using the same.
|
WO/2024/003904A1 |
The present invention is directed to combination therapies using compositions of Curcumin and Qing-Dai or extracts of plants producing thereof, and their clinical applications to the treatment of inflammatory conditions in general and to...
|
WO/2024/005211A1 |
Provided is a human Ad 5 vector etc., capable of avoiding immune response by existing antibody. The present invention is based on human adenovirus type 5 and pertains to a hexon-modified adenovirus vector in which the amino acid sequence...
|
WO/2024/006985A1 |
Described herein are fatty acid amide hydrolase (FAAH) cleavable prodrugs of compounds that modulate sphingosine- 1 -phosphate receptor 5 (S1P5), methods of making such compounds, pharmaceutical compositions and medicaments comprising su...
|
WO/2024/003784A1 |
The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase 5 inhibitor (PDE5 inhibitor) and an N- methyl-D-aspartate-receptor(NMDA-receptor) antagonist and a method ...
|
WO/2024/003390A1 |
The present invention relates to a polypeptide comprising at least one single domain antibody directed against mGluR2 for use as a biomolecule transporter crossing the blood- brain barrier (BBB), with the proviso that the polypeptide doe...
|
WO/2024/001587A1 |
A preparation method for levodopa composition microparticles for intranasal delivery, comprising: A) dissolving levodopa and an excipient to obtain a precursor liquid; B) atomizing the precursor liquid using an atomizer to obtain droplet...
|
WO/2024/005506A1 |
The present invention relates to a novel compound with inhibitory activity against NADPH oxidase 2 (NOX2) and a use thereof. The compound of the present invention, an isomer thereof, or a pharmaceutically acceptable salt thereof has the ...
|
WO/2024/005019A1 |
Provided is an agent for improving cognitive function which comprises an agonist with respect to peroxisome proliferator-activated receptor alpha (PPARα). Also provided is a pharmaceutical composition which is for treating or preventing...
|
WO/2024/006984A1 |
Provided herein are compositions relating to psychedelics and serotonin receptor modulators. Further provided herein are methods of suppressing or halting hallucinogenic effects of a psychedelic and methods of treating a disease or disor...
|
WO/2024/001964A1 |
Provided are a nimodipine composition free of ethanol and phospholipid for moist heat sterilization and a method for preparing same. The composition comprises: (1) nimodipine; (2) a non-phospholipid surfactant selected from a mixture of ...
|
WO/2024/003704A1 |
The present invention relates to a composition in a solid form, preferably in the form of a tablet, comprising differentiated release compositions based on melatonin and/or active ingredients from officinal plants and its use in a method...
|
WO/2024/003380A1 |
The present invention relates to vascular endothelial growth factor receptors (VEGFRs) inhibitors, in particular VEGFR-1 inhibitors, for use in promoting myelination and/or neuroprotection in a subject. The present invention also relates...
|
WO/2024/005561A1 |
The present application provides a composition comprising a Stewartia pseudocamellia extract as an active ingredient for prevention or treatment of dementia.
|
WO/2024/004647A1 |
The purpose of the present invention is to provide heterotrophic microalgae having a high content of γ-aminobutyric acid, and a method for increasing the content of γ-aminobutyric acid in the heterotrophic microalgae. The present inv...
|
WO/2024/006457A1 |
A method of treating or preventing Alzheimer's disease or related dementias in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Brain gene expression profiles of severe COVID-19 patients show increase...
|
WO/2024/003412A1 |
The present invention relates to a method for determining if a subject is suffering from a neuro-biomarkers, in particular neurotransmitter imbalance and to a functional food for use in the treatment or prevention of neuro-biomarkers, in...
|
WO/2024/006226A1 |
Provided are N-substituted phenylalkylamines, methods of making the same, and methods of using such compounds, for example, as receptor probes, as modulators of neurotransmission, and as therapeutic agents, for example as CNS agents. Als...
|
WO/2024/004656A1 |
Provided is a pharmaceutical composition that is a composition for treating an immune-related adverse event (irAE) in a subject who has undergone a cancer immunotherapy, the pharmaceutical composition containing anthracycline.
|
WO/2024/006750A1 |
The present invention relates to solid dispersions comprising amorphous 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-
f]indol-7-yl)-1H-pyrrole-2,5-dione and a stabilizing polymer; liquid solutions comprising 3-(5-fluoroben...
|